Furthermore, our study demonstrates that inhibiting renal MDK expression alleviates cognitive impairment and reduces microglial activation, highlighting the therapeutic potential of targeting the MDK‐LRP1 pathway in AKI‐related cognitive decline. Here, LRP1 is linked to Mental deterioration.